← Back to Search

Platinum-based Chemotherapy

Pemetrexed and cisplatin for Mesothelioma

Phase 1 & 2

Waitlist Available

Led By Majorie Zauderer, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 year

Awards & highlights

Study Summary

This trial will test the effects of pevonedistat, both good and bad, when taken alone and also in combination with standard chemotherapy.

Eligible Conditions

Mesothelioma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

maximum tolerated dose (MTD) (cohort 2)

number of patients who have a clinical benefit rate (CBR) (cohort 1)

Trial Design

2Treatment groups

Experimental Treatment

Group I: pevonedistat in combination with pemetrexed and cisplatinExperimental Treatment2 Interventions

Group II: PevonedistatExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,889 Total Patients Enrolled

19 Trials studying Mesothelioma

788 Patients Enrolled for Mesothelioma

M.D. Anderson Cancer CenterOTHER

2,973 Previous Clinical Trials

1,789,337 Total Patients Enrolled

12 Trials studying Mesothelioma

619 Patients Enrolled for Mesothelioma

Majorie Zauderer, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are Pemetrexed and cisplatin most effective in treating?

"Pemetrexed and cisplatin are most commonly used to target malignant neoplasms, but they can also be leveraged in the treatment of ovarian cancer, unresectable thymoma, and locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

Are people currently being enrolled in this trial?

"The clinical trial detailed on clinicaltrials.gov is no longer recruiting patients for participation. This particular study was posted on October 5th, 2017 and updated September 12th, 2020; however, there are 985 other trials that are still open to enrolment."

Answered by AI

How many people are being enrolled in this study?

"Recruitment for this study has ended. The listing was first posted on October 5th, 2017 and updated September 12th, 2022. For patients looking for similar studies, there are 827 trials involving Pemetrexed and cisplatin currently recruiting participants with mesothelioma."

Answered by AI

Are there a few hospitals testing this in Canada?

"To make participation more feasible, the 9 sites running this trial are located near major metropolitan areas including New york, Montvale and Rockville Centre."

Answered by AI

Are there any other ongoing or completed investigations looking at Pemetrexed in combination with cisplatin?

"Pemetrexed and cisplatin were first studied in the year 1997 at City of Hope Comprehensive Cancer Center. To date there have been 1125 completed trials. There are presently 827 actively recruiting trials, with a large number of these studies running out of New york, New jersey."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

2017. "Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03319537.